Sarcoma: cross-border specialty drug access for international patients

Quick orientation

Sarcomas collectively account for approximately 1 percent of adult cancers and 15 percent of pediatric cancers. Individually, most subtypes are rare.

Typical age of onset. All ages; subtype-specific. Pediatric sarcomas are distinct from adult disease.

Severity tiers. Severity depends on histology, grade, and stage.

Why specialty drugs for Sarcoma are hard to access internationally

Targeted therapies for sarcoma subtypes including synovial sarcoma, gastrointestinal stromal tumor (GIST), and tenosynovial giant cell tumor are recent additions. International registration is uneven.

Treatments approved by the FDA

• Tecelra (afamitresgene autoleucel) — FDA approval: 2024. Mechanism: Autologous SPEAR T-cell therapy for HLA-A*02-positive MAGE-A4-expressing synovial sarcoma. Route: One-time intravenous infusion of autologous engineered T-cells. US WAC ballpark: Approximately USD 700,000 one-time. Country pricing: Qatar · Egypt · Oman.
• Romvimza (vimseltinib) — FDA approval: 2025. Mechanism: CSF1R inhibitor for tenosynovial giant cell tumor. Route: Oral. US WAC ballpark: Approximately USD 290,000 per year. Country pricing: Kuwait · Bahrain · Lebanon.
• Krazati (adagrasib) — FDA approval: 2022. Mechanism: KRAS G12C inhibitor (sarcoma subset). Route: Oral twice daily. US WAC ballpark: Approximately USD 230,000 per year. Country pricing: Saudi Arabia · Kuwait · Egypt · Jordan.
• Ogsiveo (nirogacestat) — FDA approval: 2023. Mechanism: Gamma-secretase inhibitor for desmoid tumors (soft-tissue tumor adjacent). Route: Oral twice daily. US WAC ballpark: Approximately USD 240,000 per year. Country pricing: Saudi Arabia · Egypt.

Cross-border pathways used for Sarcoma

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Medical Tourism Access

What your physician needs to know

• Confirm sarcoma subtype by pathology with molecular profiling.
• Document HLA typing for cell therapy eligibility where relevant.
• Sarcoma center co-management is the standard.
• Some therapies require qualified administration centers.
• Imaging and response assessment with treating team.

Common questions

Can I receive Tecelra abroad?

Tecelra is administered at qualified centers, primarily in the US. Reserve Meds supports medical-tourism access.

How is HLA typing handled?

Where local typing is unavailable, samples can be referred to qualified labs.

Are oral targeted therapies available locally?

Some are; others are not. Registration varies. We confirm by destination.

How long does shipment take?

Five to fifteen business days for oral products; cell therapies require travel.

What documents are required?

Oncologist's prescription, pathology with molecular profile, HLA type where relevant, and treatment history.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Sarcoma, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Sarcoma

Reserved for you.